Skip to main content
Premium Trial:

Request an Annual Quote

Canine Consumer Genomics Firm Embark Veterinary Raises $10M

NEW YORK (GenomeWeb) — Canine consumer genomics firm Embark Veterinary said today that it has closed a $10 million Series A financing round.

The round was led by F-Prime Capital and included existing investors Slow Ventures, Section 32, Third Kind Venture Capital, Freestyle Capital, FJ Labs, and 23andMe CEO Anne Wojcicki. It follows a $4.5 million funding round in mid-2017.

Boston-based Embark offers a DNA test for dogs to consumers and breeders that it said can provide information on breed, ancestry, health, and disease risk. The company said it will use the newly raised funding to continue building its canine genetics database and expand its staff. Last year, Embark tripled its database, which it said now contains "in the hundreds of thousands" of dog DNA samples.

"Embark provides that critical information with comprehensive and accurate testing that is unique in canine genetics," Embark Cofounder and CEO Ryan Boyko said in a statement. "This round of funding allows us to move faster to provide more information to existing customers while doubling down on research to ensure that all dogs live healthier lives."

Embark competes with several other firms in the dog genetic testing space, including Mars Petcare's Wisdom Health, OptiGen, and Paw Print Genetics.